Introduction
============

Among EU countries, Italy, together with Spain, Greece, Portugal, and Great Britain, has a high frequency of isolation of methicillin-resistant *Staphylococcus aureus*(MRSA) in hospitals. After an initial and continuous increase between 1994 and 2001 \[[@B1]\], the annual reports from EARSS (1999--2007) described the isolation of MRSA from bloodstream infections in 1999 as 40%, but, unlike the trend in other European countries such as Great Britain or Greece, a constant small average decrement was registered in the 2001--2007 period, reaching an average value of 33.7% in 2007 <http://www.earss.rivm.nl>.

These data are only partially representative of the Italian nosocomial MRSA prevalence. MRSA is responsible for various infections and considerable variations between institutions and wards, often in the same geographical areas, exist, demonstrating that MRSA prevalence, in some settings, significantly exceeds previous estimates \[[@B1]\], sometimes accounting for approximately 40--60% of all hospital acquired strains \[[@B2]-[@B5]\]. There could be many explanations for these differences: infection control measures, antibiotic prophylaxis and treatments used in each ward/hospital and, not less important, the clonal and often epidemic nature of these microrganisms. Certain strains can be found worldwide yet only few clones are responsible for most MRSA infections \[[@B1],[@B6],[@B7]\].

Analysis of more than 3,000 isolates from Southern Europe, the United States, and South America, showed that nearly 70% of them belonged to five major pandemic clones, namely the Iberian (ST 247-MRSA-IA), Brazilian (ST239-MRSA-IIIA), Hungarian (ST239-MRSA-III), New York/Japan (ST5-MRSA-II), and Pediatric (ST5-MRSA-IV) clones \[[@B8]\]. Dominant and minor lineages constitute the *S.aureus*population \[[@B9]\]. Each lineage is remarkably distinct and isolates of the same lineage, but from diverse geographical locations or from different periods, can be remarkably similar (except for their mobile genetic element -- MGE -- contents that account for 10--20% of the *S.aureus*chromosome) \[[@B10],[@B11]\]. Evolution of lineages happened independently by different mechanisms \[[@B12]\] and MGEs encoding virulence and resistance genes can move into and out of strains.

In recent years, the widespread use of antibiotics has undoubtedly accelerated the evolution of *S.aureus*, and led to the emergence of strains that have systematically acquired multiple resistance genes \[[@B1],[@B13]\]. With the current emergence of multi-drug resistant isolates in hospitals on the one hand \[[@B14]\] and the dramatically increased incidence of hyper-virulent community-associated MRSA (CA-MRSA) on the other \[[@B15],[@B16]\], MRSA has been able to evolve rapidly and create new clinical problems.

A greater understanding of how the bacteria have evolved in any geographical area can help us to rapidly identify new outbreak strains and even prevent emergence and diffusion of more resistant clones \[[@B17]\].

There have been only few studies reporting the dynamics of MRSA over long periods of time \[[@B18]-[@B23]\]. In almost all these studies, despite the worldwide predominance of a few MRSA clones, the authors demonstrated local strain diversity and reported that predominant MRSA strains seemed to change over time and emerging clones were appearing or replacing the oldest.

The aim of our study was to trace the dynamics of genotypic changes and the shifts in the levels of susceptibility to antibiotics, including glycopeptides, of MRSA lineages in Italy, comparing the genotypic backgrounds of contemporary isolates with those of a sample of early MRSA strains from 1980. The study also provides a complete overview of predominant and sporadic MRSA strains in our country, over a period of 17 years, from two surveillances projects (1990--1998 and 2000 -- 2007).

Methods
=======

Isolates
--------

Three hundred and one MRSA clinical isolates, recovered from 19 Italian hospitals between 1990 and 2007 were selected from two *Staphylococcus aureus*collections, which were sent to our laboratory during previous multi-centre studies. The first collection (called A throughout the text) of 160 strains was selected as non-repetitive isolates representative of the different parts of Italy from among 426 methicillin-resistant *S.aureus*(MRSA) strains isolated in the period 1990--1999 \[[@B24]\]. The second group of 141 strains (called B), were isolated in the period 2000--2007, and were selected with the same criteria described above, from among approximately 1,000 different *S.aureus*isolates \[[@B25]\].

Both groups of isolates were from various clinical specimens and in particular, group A: 37% of cases from lower respiratory tract specimens, 29% from blood cultures (7% associated to a CVC), 1% from cerebrospinal fluid, and 31% from SSSIs. Group B isolates were almost comparable, with a greater percentage only for lower respiratory tract specimens (53%), 19% from blood cultures, 3% from cerebrospinal fluid and 25% from SSSIs.

A sample of fifteen early MRSA strains from 1980 was used for comparison \[[@B26]\].

All isolates were re-identified at the species level by catalase test, *S. aureus*agglutination test (STAPHYLASE TEST; Oxoid Ltd. Basingstoke, Hampshire, UK) and biochemical tests (API-Staph system; bio Mérieux SA, Marcy-l\'Etoile, France). All strains were stored at -80°C until use. Methicillin-resistance was evaluated by disk diffusion method, and correlated to the presence of the *mec*A gene (see below).

The distribution of strains throughout Italy was, in both projects, approximately 20% from hospitals in Northern Italy, 35% from the center, and 45% from Southern Italy.

*In vitro*susceptibility testing of antibiotics
-----------------------------------------------

The antimicrobial susceptibility profiles of the 301 MRSA strains to the main classes of antibiotics were determined by using the Kirby-Bauer method, according to CLSI guidelines \[[@B27]\]. The MRSA isolates were tested against a panel of 9 antimicrobial agents as follows: oxacillin-1 μg, ciprofloxacin-5 μg, chloramphenicol-30 μg, gentamicin-10 μg, erythromycin-15 μg, clindamycin-2 μg, trimethoprim-sulfamethoxazole-25 μg, rifampin-5 μg and tetracycline-30 μg.

*In vitro*susceptibility testing for vancomycin, teicoplanin, quinupristin/dalfopristin, linezolid, tigecycline and daptomycin was further performed by the broth microdilution method to determine the minimum inhibitory concentrations (MICs), following the CLSI guidelines \[[@B27]\]. All antibiotics were kindly provided, as standard reference powders, by the following manufacturers: daptomycin from Novartis (Basel, CH); linezolid from Pfizer (Groton, CT, USA); quinupristin/dalfopristin and teicoplanin from Aventis (West Malling, UK). Vancomycin was from Sigma Chemical (St. Louis, MO, USA).

MICs were determined using Muller-Hinton broth (Oxoid, Milan, Italy), and for daptomycin tests the broth was supplemented to yield a final concentration of 50 mg/L calcium. *S. aureus*ATCC 29213 was used as quality control. Results were read after incubation at 37°C for 18--24 h. Susceptibility to daptomycin was defined as a MIC value of ≤ 1 mg/L; CLSI guideline MIC breakpoints were used for all the other antibiotics tested \[[@B27]\].

Pulsed-field gel electrophoresis (PFGE)
---------------------------------------

Genomic DNA was prepared in agarose plugs as previously described \[[@B28]\]. DNA was digested with 20 U of *Sma*I (BioLabs, New England, USA) at 30°C overnight. PFGE was carried out in a CHEF-DR II apparatus; (Bio-Rad, CA, USA). Macrorestriction fragments were separated on 1% (wt/vol) ultra pure agarose gels (Sigma Aldrich, S.Louis, MO, USA) at 6 V/cm for 21 h at 14°C, with pulse times of 5 s -- 35 s, to separate *Sma*I patterns. Lambda DNA concatemers (New England BioLabs, Beverly, MA, USA) were used as molecular size markers.

Similarities among macrorestriction patterns were previously identified according to established criteria \[[@B29]\] in each of the three time frames. The comparison of similarities among groups for a long-term evaluation was performed by using the type strain of each PFGE profile of each time frame as internal standard.

PCR and SCCmec typing
---------------------

Genomic DNA was extracted from all bacterial cultures and used as a template for amplification. All isolates were screened for the presence of the *mec*A gene. PCR experiments were carried out following procedures previously published \[[@B28]\]. PCR products were analyzed by electrophoresis on 1% agarose gels (Sigma Aldrich, Saint Louis Mo, USA).

The amplification procedure for the detection of the Panton-Valentine Leukocidin (PVL) was performed as previously published \[[@B16]\].

The SCC*mec*cassettes were first determined by a multiplex-PCR protocol previously described, and assigned to the corresponding types \[[@B30]\]. Furthermore, the results were confirmed by different multiplex-PCR protocols, focusing on the *mec*gene complex and the *ccr*gene complex \[[@B31]\].

Molecular typing
----------------

All strains were grouped into clonal groups on the bases of their antibiotype, PFGE profile and SCC*mec*type, and representative isolates of the main PFGE sub-types A, B and E were further characterized by Multi Locus Sequence Typing (MLST), while all the other strains belonging to PFGE C, G, sporadic clones and 1980 strains were sequenced.

The clones were typed following the current nomenclature (ST-MRSA-SCC*mec*), except in those contexts in which maintaining the old nomenclature is necessary to understand the diversity existing in each MLST profile.

The sequences of the seven housekeeping genes used for MLST, corresponding to the allelic profile *arc*C-*aro*E-*glp*-*gmk*-*pta*-*tpi*-*yqi*L, were obtained by comparing the sequences obtained with those in the MLST database <http://mlst.zoo.ox.ac.uk>\[[@B32]\]. All STs described in the study were deposited on the MLST website and were compared with the major international *S. aureus*STs published.

Statistical analysis
--------------------

Glycopeptide MIC trends over the 17 years were assessed using non-parametric methods. Chi-square and Fisher\'s exact tests were performed and significance was defined as P \< 0.001.

Results
=======

Description of MRSA clones
--------------------------

The majority of MRSA clones in Italy, in agreement with the results of a previous study on strains isolated in 1990, belonged to six major clones: ST8-MRSA-I, ST247-MRSA-IA, ST239-MRSA-IIIA, ST228-MRSA-I, ST247-MRSA-I/IA and ST22-MRSA-IV and several minor clones. All these strains were previously typed by PFGE analysis (together with *Cla*I/*mec*A and *Cla*I/Tn*554*and SCC*mec*), and grouped in six MRSA clones previously known as Archaic and Iberian (PFGE profile A, including, in both periods of time, 32 closely related sub-types), Brazilian (PFGE profile B, with 6 sub-types), Italian (PFGE profile E, with 10 sub-types), Rome (PFGE profile C) and Gentamicin-Susceptible (PFGE profile G).

Figure [1a](#F1){ref-type="fig"} shows the distribution of the MRSA clones in the A and B periods covering seventeen years. The beginning of the 1990s was characterized by the presence (16% of isolates) of ST8, carrying the SCC*mec*type I. In 1993--1995, one major international epidemic clone, ST247-MRSA-IA, appeared in our hospitals (23%), together with ST228-MRSA-I circulating in our country (29%).

![**Description of MRSA clones**. a) Distribution of the MRSA clones in periods A (1990--1999) and B (2000--2007); b) Description of the molecular backgrounds (ST, SCC*mec*and CC) of main clones isolated in Italy, correlated to their previous names; c) Graphical representation of alternation of MRSA clones in Italy during the 27-year period of study. \*Italian and Southern Germany clones belong to the same ST228-MRSA-I, but they differ for their PFGE profile. \*\*UK EMRSA-15 was often reported in literature as gentamicin-susceptible MRSA (GS-MRSA) clone. (ST: Sequence-Type; SCC*mec*: Staphylococcal Cassette Chromosome *mec*; CC: Clonal-Complex).](1476-0711-8-22-1){#F1}

Another international clone, ST239-MRSA-IIIA, found to be resistant to cotrimoxazole, appeared in our hospitals around 1994 (9%), together with the local clone ST247-MRSA-I/IA, showing different phenotypic and genotypic features (erythromycin and clindamycin susceptibility; PFGE C), named Rome clone to differentiate it from the Iberian one. It appeared at the same time as ST239-MRSA-IIIA, but it has only been detected sporadically to date.

In 2000, we saw the decrease of ST247-IA (6% of isolates), the increase of ST228-I (57%), but also the re-appearance of ST8 (UK EMRSA-2/-6) carrying the SCC*mec*IV (7% of strains) instead of the SCC*mec*I, characteristic of the period between 1985--1990 (data not shown). Besides the major international clones, the isolation of a gentamicin-susceptible one, ST22-MRSA-IV, was detected in some hospitals, reaching 14% of isolates.

The *lukF*-PV and lukS-PV genes were detected in three CA-MRSA strains, belonging to ST8 and ST30, carrying SCC*mec*IV, and ST88, carrying SCC*mec*V.

The original and current nomenclature and molecular characteristics of each clone are shown in Figure [1b](#F1){ref-type="fig"}.

The group of strains isolated in 1980 was included for comparison (15 strains); ST8-MRSA-I (4 strains), remaining 11 strains belonged to ST1-MRSA-I (2 strains), ST15-MRSA-I (4 strains) and ST30-MRSA-I (5 strains), while of these 11 only 4 strains carried a variant of SCC*mec*type I. In particular those belonging to ST1-MRSA-I~like~(1 strain) and ST15-MRSA-I~like~(1 strain) carried *ccr*A~2~B~2~recombinases instead of *ccr*A~1~B~1~, while ST30-MRSA-I~like~(2 strains) did not carry any recombinases genes (figure [1c](#F1){ref-type="fig"}). SCC*mec*multiplex PCR assays did not show any difference between the common type I (*pls*, *mec*A and *dcs*loci) and the variant. Recombinases multiplex PCR and LONG-PCR experiments in those strains carrying *ccr*A~2~B~2~recombinases, revealed a unusual fragment, of about 9 Kb, from the *pls*gene (*cif*F, primer up) to *ccr*A~2~B~2~(*ccr*B2, primer dw).

Figure [1c](#F1){ref-type="fig"} also graphically represents the alternation of diverse clones over the 27 year time frame. Considering the strains isolated in 1980, it can be seen that, with the only exception of ST8, all the other clones disappeared from hospitals. In our results, this clone, i.e. the early ST8-MRSA-I (variable PFGE profiles), underwent a sort of evolution passing from an ST8-MRSA-I (PFGE A, with 3 sub-types) to the MDR ST247-MRSA-IA (PFGE A, with 28 sub-types) and back again to a more susceptible clone i.e the ST8-MRSA-IV (PFGE A, 1 sub-type) isolated in 2007. A characteristic of the clones at the end of period A and the beginning of period B is their multi-drug resistance, while the majority of period B saw a reduction in the number of these clones and a tendency towards susceptibility with the appearance of ST8-MRSA-IV and ST22-MRSA-IV -- reflecting what was found in 1980, and indicating a possible future clinical change.

Antibiotic susceptibilities
---------------------------

All the 301 MRSA strains were tested for their susceptibility to all classes of antibiotics. With the only exception of the strains isolated in 1980 that were uniformly susceptible to all non-beta lactam antibiotics, the remaining isolates were multi-resistant (Table [1](#T1){ref-type="table"}). Both groups -- A and B -- acquired and maintained their level of resistance to gentamicin (98.1 and 88% respectively), erythromycin (83.1 versus 83.7%), clindamycin (85 and 75%) and ciprofloxacin (97 and 96.5). On the contrary, the isolates of group A were 67% resistant to tetracycline, while only 21% of group B isolates were resistant to this drug. The same decrease was observed for rifampin (from 66.2% to 21%) and cotrimoxazole (42 to 8.5%). The 15 MRSA strains from 1980 had from 73.3 to 86.6% susceptibility to all these drugs.

###### 

Antibiotic-resistance (%) of various antibiotics against 301 MRSA strains, compared with a sample of Italian isolates from 1980.

  **Antibiotics**   **MRSA isolated in 1980 (15)**   **MRSA isolated in 1990--1999 (period A) (160)**   **MRSA isolated in 2000--2007 (period B) (141)**                     
  ----------------- -------------------------------- -------------------------------------------------- -------------------------------------------------- -------- -------- ------
                    S                                R                                                  S                                                  R        S        R
  Gentamicin        73.3                             26.6                                               1.9                                                98.1     22\*\*   88
  Erythromycin      86.6                             13.3                                               16.9                                               83.1     16.3     83.7
  Clindamycin       86.6                             13.3                                               15                                                 85       35       75
  Tetracycline      73.3                             26.6                                               33.1                                               67       82.2°    17.8
  Ciprofloxacin     80                               20                                                 3                                                  97       3.5      96.5
  Rifampin          73.3                             26.6                                               33.7                                               66.3\*   79       21
  Cotrimoxazole     86.6                             13.3                                               58.1\*\*\*                                         42       91.5     8.5

\* Rifampin resistance is characteristic of CC8 (ST247 and 239)

\*\* Including the gentamicin-susceptible clone

\*\*\* Cotrimoxazole resistance is a marker of ST 239

° The tetracycline susceptible Italian clone increased in this period

The measure of the temporal shift in the susceptibility level of the anti-staphylococcal drugs, namely glycopeptides, linezolid, quinupristin/dalfopristin, daptomycin and tigecycline, was observed stratifying all the MIC data with respect to time. This distribution is shown in Figure [2](#F2){ref-type="fig"}. Making a comparison among MIC~90~values, linezolid was stable in periods A and B with a MIC~90~value of 2 mg/L; the same was true for quinupristin/dalfopristin (MIC~90~of 1 mg/L in both periods), and for glycopeptides (2 and 4 mg/L for vancomycin and teicoplanin respectively). All isolates of the 1980 group were uniformly more susceptible to all antibiotics, as was predictable.

![**MIC distributions of the major anti Gram-positive drugs against MRSA strains**. MIC~50~and MIC~90~in bold and underlined; MIC~50~only in bold; MIC~90~in grey.](1476-0711-8-22-2){#F2}

A MIC distribution evaluation demonstrated that the most striking change was a slight but continuous shift in vancomycin and teicoplanin MIC~s~over time. Table [2](#T2){ref-type="table"} shows this phenomenon in the three major clones, ST239-MRSA-IIIA, ST247-MRSA-IA and ST228-MRSA-I, isolated in Italy in periods A and B. While the percentage of strains with susceptibility to vancomycin of ≤ 0.5 mg/L was 52% in period A, this value decreased to 20.4% in period B with a corresponding increase in the number of strains with a MIC of 1 mg/L (44.1 versus 28.5%) and ≥ 2 mg/L (35.5% versus 19.4%). The same trend was observed for teicoplanin.

###### 

Number of MRSA strains with glycopeptide MICs of ≤ 0.5, 1, and ≥ 2 mg/L in ST247-MRSA-IA, ST239-MRSA-IIIA and ST228-MRSA-I isolated in periods A and B

                        **ST247-MRSA-IA, ST239-MRSA-IIIA and ST228-MRSA-I clones° 1990--1999 -- period A (98)**   **ST247-MRSA-IA, ST239-MRSA-IIIA and ST228-MRSA-I clones° 2000--2007 -- period B (93)**                                       
  --------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------- ----------- ----------- -----------
  **MIC mg/L**          ≤ 0.5                                                                                     1                                                                                         ≥ 2         ≤ 0.5       1           ≥ 2
  **Vancomycin (%)**    51 (52)                                                                                   28 (28.5)                                                                                 19 (19.4)   19 (20.4)   41 (44.1)   33 (35.5)
  **Teicoplanin (%)**   49 (50)                                                                                   25 (25.5)                                                                                 22 (22.4)   20 (21.5)   30 (32.2)   43 (46.2)

° P \< 0.001

Interestingly, this MIC creep was related to the parallel increase in the isolation of the MDR ST228-MRSA-I clone, in period B.

Discussion
==========

We studied 2 collections of MRSA strains identified over a 17-year period in Italy (periods A and B). These strains are representative of isolates collected during this time and published in two Italian surveys \[[@B24],[@B25]\]. The results were compared with those obtained from a group of Italian MRSA strains isolated in 1980. This report describes the evolution of the major Italian clonal types and the evolution of their resistance to antibiotics. Due to the vast amount of data that we had collected every year, we used representative phenotypes of each year over the two survey periods.

The comparison of these data with those from 1980 gives important and unique insights into long-term MRSA evolution.

The presence of five major clones (ST8-MRSA-I, ST247-MRSA-IA, ST239-MRSA-IIIA, ST228-MRSA-I and ST247-MRSA-I/IA) was previously reported by Mato R. et al. in 1990 \[[@B7]\]. We demonstrate here that the prevalence of predominant clones changed over time and this change might have significant medical consequences, since the new clones often display different antibiotic resistance profiles. We also demonstrate that -- during this time -- there was a considerable increase in the prevalence of MDR clones, with the Italian one becoming predominant in our country. Furthermore, we demonstrate that the isolation of MRSA strains with a vancomycin MIC ≥ 2 mg/l is more frequent in the nosocomial-acquired strains of the B period, and that this shift is also present for teicoplanin.

Epidemiological evolution of MRSA clones
----------------------------------------

All major circulating clones in Italy belonged to the 4 most common genetic background types (ST8, ST247, ST239, and ST228) and they have also been reported, for a long time, as main isolates from studies of HA-MRSA all around the world. Among these clones, ST228 was prevalently found in Europe and was first isolated in 1995 in South-Germany, Slovenia, Austria, and Italy \[[@B33],[@B34]\]. This clone still represents, in our country, the most common HA-MRSA clone, it is not related to any other national clones, and its genetic background closely correlates with those of several *S.aureus*including MSSA, MRSA, and VISA, all belonging to the clonal complex 5 (CC5), confirming the role of horizontal transfer of *mec*A among different ancestral lineages, originating from a well adapted MSSA strain. In our country, this clone doubled its prevalence during the study period, accounting for more than half of the MRSA strains isolated in period B.

The evolutionary history of clones belonging to CC8 (ST8-MRSA-I, ST247-MRSA-IA, ST247-MRSA-I and IA, and ST8-MRSA-IV) is more complex. The acquisition of diverse SCC*mec*elements and/or other genetic elements, likely occurred in several occasions in this genetic background \[[@B8]\]. The few CC8 1980 clones in our study, shared SCC*mec*cassettes similar to SCC*mec*type I, probably their precursors.

During period A, we documented the evolution of the ST8-MRSA-I towards a more resistant phenotype, acquiring and integrating different genetic elements, in particular the plasmid pUB*110*(carrying kanamycin and neomycin resistance genes) into the SCC*mec*region, giving the original type I cassette a more complex organization (SCC*mec*IA), and two copies of Tn*554*(carrying erythromycin and spectinomycin resistance determinants) integrated in the genome. This clone, although being more resistant to antibiotics, maintained the same PFGE profile A (with diverse sub-types), and belongs to ST247, a single locus variant of ST8.

ST239-MRSA-IIIA had a short history in Italy, probably because it had come from other countries \[[@B35]\]. This clone is poorly represented in both periods A and B.

Period A was also characterized by the emergence of a local clone (Rome clone) possessing the same ST247 of the more diffused Iberian one, but with two different important characteristics: i) a different PFGE profile; ii) a predisposition to low level susceptibility to vancomycin, producing an hVISA phenotype \[[@B32]\]. The replacement of ST247 in recent years (period B) in our country has also involved this clone, which is now scarcely represented.

The decline, during period B, of ST247-MRSA-IA is documented in this study. Recent reports have shown that this clone was replaced by other pandemic clones \[[@B23],[@B35]-[@B38]\]. The replacement of ST247-MRSA-IA might suggest that it had lost its epidemic potential during the last decade.

Also during period B, in which ST228-MRSA-I consolidated its presence and ST247 decreased, there was the re-appearance of ST8, carrying a different SCC*mec*type IV, that resembles the ancient one, being less resistant to antibiotics. In fact, the recent appearance of this clone is of interest, because it maintained a profile of antibiotic-susceptibility.

Finally, in the last two years of period B, different MRSA strains such as the gentamicin-susceptible ST22-MRSA-IV strain, appeared in different wards in some Italian hospitals. This appearance was accompanied, in the community, by the isolation of hyper-virulent, *pvl*-positive MRSA strains, belonging to ST8-MRSA-IV, ST30-MRSA-IV and ST88-MRSA-V, which we documented in Italy \[[@B15],[@B39]\].

Evolution of antibiotic-resistance
----------------------------------

The multi-drug resistant phenotype is a particular characteristic of the methicillin-resistant *S.aureus*strains, almost related to the global presence and spread of MDR clones \[[@B14],[@B40]\]. The homogeneous insusceptibility to all beta-lactams, characteristic of methicillin-resistant strains, together with the continuous accumulation and organization of many resistance genes, has made this species particularly difficult to treat. This diffused antibiotic-resistance is true for many classes of antibiotics such as aminoglycosides, macrolides, lincosamides, and fluoroquinolones, which, as demonstrated in this paper on contemporary isolates, appeared to maintain a low level of activity against MRSA. A notable exception seems to be the increased level of susceptibility to gentamicin found in MRSA isolated in period B, mainly due to the appearance, in our hospitals, of a gentamicin-susceptible clone, belonging to ST22.

The percentage of resistance to tetracycline, rifampin and cotrimoxazole, increased in period A, but decreased in period B: in this case the different antibiotic susceptibility patterns are linked to the epidemiologic change and replacement of clones with specific markers of resistance. In our study, the decrease in resistance to these three drugs is due to the replacement of the rifampin resistant ST247-MRSA-IA, ST239-MRSA-IIIA and ST247-MRSA-I/IA with the tetracycline susceptible ST228-MRSA-I \[[@B7]\].

The trend of susceptibility to the most used anti-MRSA drugs, as evaluated in our study, demonstrated that no resistance to vancomycin, teicoplanin, daptomycin, linezolid and quinupristin/dalfopristin was observed in the time frame of the study. Among these drugs, only daptomycin has recently been approved and marketed, explaining the substantial stability of the MIC~50~and MIC~90~over time. On the contrary, the evaluation of the MICs of the population of MRSA demonstrated something comparable to that observed for other classes of drugs: the strains isolated in period B, in which MDR clones were replaced by others with different resistance make-ups, show a distribution toward the lowest MIC concentrations. The same can be observed for quinupristin/dalfopristin.

Although reports of linezolid resistance in *S.aureus*are increasing \[[@B41],[@B42]\] data on MIC creep are infrequent (Golan Y et al, Abstract from the 46^th^ICAAC, San Francisco CA 2006; Abs C2-1157 p. 127). In our study, changes in distribution of susceptibility for linezolid are comparable in the two periods, demonstrating a one dilution increase in MIC only if compared with the susceptibility demonstrated during 1980. This creep towards higher levels of MICs is clear if glycopeptides are considered and mostly related to the increased isolation of the MDR ST228-MRSA-I clone in period B. This slight but continuous increase in the level of susceptibility of vancomycin was reported by many studies all around the world \[[@B14],[@B43],[@B44]\], many of them demonstrating a strict correlation between increased MIC values and therapeutic failure in infections sustained by MRSA \[[@B43],[@B45],[@B46]\]. The MIC creep phenomenon has produced conflicting results most likely due to the MIC statistics used \[[@B47],[@B48]\]. Reports from large multicenter studies have not demonstrated changes in vancomycin susceptibilities over time \[[@B44]\]. However, these types of studies are not designed to detect subtle changes in MICs. As reported by other investigators, we demonstrate a statistically significant increase in MRSA vancomycin and teicoplanin MICs over time. The magnitude of this increase was similar in both drugs, but the largest increase was observed for vancomycin, in which strains showing a MIC \> 1 mg/L increased from 47 to 78%.

In conclusion, we document here the alternation of multi-drug resistant MRSA clones in the 1990--2007 period, with the establishment of ST228-MRSA-I in our country, with respect to the clones present in 1980. The increase of the glycopeptide MIC levels, reflecting a worldwide trend, was also documented, due to the massive use of these drugs in clinical practice. We detected ST1, ST8, ST15, and ST30 in the 1980 isolates; thus we hypothesize their re- appearance as backgrounds for the current CA-MRSA clones, due to mechanisms as yet unknown.
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